MedTrace Logo

A Phase II Study to Evaluate JMKX000197 Injection Versus Cisplatin in the Treatment of Malignant Pleural Effusion

NCT07649369 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2026-06-16

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of intrapleural JMKX000197 compared with intrapleural cisplatin in patients with malignant pleural effusion.

Conditions

  • Malignant Pleural Effusions (Mpe)

Interventions

DRUG

JMKX000197

Intrapleural administration

DRUG

Cisplatin

Intrapleural administration

Sponsors & Collaborators

  • Shanghai Jeyou Pharmaceutical Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Jie Wang · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-17
Primary Completion
2028-01-12
Completion
2028-08-14

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07649369 on ClinicalTrials.gov